PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial
Martin H. Voss(Memorial Sloan Kettering Cancer Center), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center), James J. Hsieh(Memorial Sloan Kettering Cancer Center), Venkatraman Seshan(Memorial Sloan Kettering Cancer Center), Irina Ostrovnaya(Memorial Sloan Kettering Cancer Center), Jiayuan Shi(Bristol-Myers Squibb (Germany)), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), Xia Han(Mechanical Solutions (United States)), Jianning Xu(Kettering University), Parul Patel(Novartis (United States)), Ying‐Bei Chen(Memorial Sloan Kettering Cancer Center), Mahtab Marker(Novartis (United States)), Albert Reising(Mechanical Solutions (United States))
Cited by 38
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k